Skip to content

    Panelists Still Cite Need for Continued Research on Heart Valve Risk

    May 10, 2012 (Silver Spring, Md.) -- An FDA advisory committee voted 18-4, with one abstention, that the agency should approve lorcaserin, which would make it the first new prescription weight loss drug in more than a decade.

    Although the FDA does not have to follow the advice of its advisory panels, it usually does.

    Arena Pharmaceuticals wants to market lorcaserin for weight loss and maintenance in obese adults whose body mass index, or BMI, is at least 30, and in overweight adults with a BMI of at least 27 who also have one or more weight-related medical problems, such as high blood pressure, heart disease, sleep apnea, or type 2 diabetes. A 5-foot-7-inch person who weighs 192 has a BMI of 30; at 173 pounds, a person that height has a BMI of 27.

    Concerns about heart valve problems helped spur the advisory panel to vote 9-5 against recommending approval of lorcaserin in September 2010. Committee members' other safety concerns included psychiatric problems such as psychosis and breast and brain tumors seen in rats given the drug. Meanwhile, patients who took lorcaserin lost only a bit more weight than those given a placebo.

    In October 2010, the FDA turned down lorcaserin, citing the modest weight loss and worries about its potential to cause cancer. In response, Arena submitted more material to the agency, including a trial of the drug in 604 patients with type 2 diabetes.

    After a year in the study, diabetes patients given lorcaserin lost 3.1% more weight than those on a placebo, below the 5% difference the FDA has set as one criterion for weight loss drugs, FDA medical officer Julie Golden, MD, said.

    However, she said, lorcaserin did meet the other criterion: After a year of treatment, 38% of patients on lorcaserin lost at least 5% of their body weight, compared to 16% of those on placebo.

    'Lingering Uncertainty'

    Although he voted in favor of approval, Jack Yanovski, MD, PhD, chief of the section on growth and obesity at the Eunice Kennedy Shriver National Institute of Child Health and Human Development, said he was "not at all convinced" that Arena had provided enough evidence to show that lorcaserin did not raise the risk of breast tumors.

    Healthy Recipe Finder

    Browse our collection of healthy, delicious recipes, from WebMD and Eating Well magazine.

    Top searches: Chicken, Chocolate, Salad, Desserts, Soup

    Heart Rate Calculator

    Ensure you're exercising hard enough to get a good workout, but not strain your heart.

    While you are exercising, you should count between...